Skip to main content
Clinical Trials/NCT03330704
NCT03330704
Withdrawn
Early Phase 1

Randomized Controlled Trial for the Use of Patient Tailored Balanced Hypertonic Solutions in Patients With Cerebral Edema

Stanford University1 site in 1 countryNovember 28, 2017

Overview

Phase
Early Phase 1
Intervention
3% Sodium Chloride
Conditions
Cerebral Edema
Sponsor
Stanford University
Locations
1
Primary Endpoint
Total volume of intravenous hypertonic fluid administered to the patient
Status
Withdrawn
Last Updated
6 years ago

Overview

Brief Summary

Many patients with traumatic brain injuries (including strokes, blood clots, or other brain injuries) are given concentrated salt water solutions (hypertonic saline) in order to treat brain swelling (cerebral edema). Current therapies consist of a mixture of sodium and chloride, which can lead to high levels of serum chloride and increased total body water. High levels of chloride can cause acidosis, which can cause the body to function sub-optimally. Therefore, the investigators are proposing to use two concentrated solutions in these patients at the same time that will allow for a lower total volume of solution administration and reduce the rise in chloride to prevent acidosis. The main outcome will therefore be the patients sodium level, chloride level and serum pH.

Registry
clinicaltrials.gov
Start Date
November 28, 2017
End Date
January 1, 2020
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Tim Angelotti

Associate Professor of Anesthesiology

Stanford University

Eligibility Criteria

Inclusion Criteria

  • Able to consent
  • 18 years or older
  • English speaking
  • Clinical indication (intracranial hypertension from cerebral edema) for hypertonic fluid administration

Exclusion Criteria

  • Fails to consent
  • \< 18 years old
  • Hypertonic therapy not indicated

Arms & Interventions

Standard Therapy

This group will receive 3% hypertonic sodium chloride for the management of their cerebral edema. 3% Sodium Chloride is the generic name of this intravenous fluid preparation.

Intervention: 3% Sodium Chloride

Balanced Therapy

This group will undergo two simultaneous infusions. 23.4% sodium chloride and 8.4% sodium bicarbonate will be infused at the same time in various ratios for management of cerebral edema with a balanced approach

Intervention: 23.4% Sodium Chloride

Balanced Therapy

This group will undergo two simultaneous infusions. 23.4% sodium chloride and 8.4% sodium bicarbonate will be infused at the same time in various ratios for management of cerebral edema with a balanced approach

Intervention: 8.4% Sodium Bicarbonate

Outcomes

Primary Outcomes

Total volume of intravenous hypertonic fluid administered to the patient

Time Frame: The fluid will be infused until the new serum sodium goal is achieved. This outcome measure will be assessed 1 week after study enrollment

Total hypertonic fluid volume administered to each group of patients measured in milliliters of fluid.

Secondary Outcomes

  • Urine output(Urine output during active hypertonic fluid infusion will be measured. This outcome measure will be assessed 1 week after study enrollment)

Study Sites (1)

Loading locations...

Similar Trials